- Home
- HG vs SLNO Comparison
HG vs SLNO Comparison
Compare HG & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | SLNO |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HG | SLNO |
|---|---|---|
| Price | $26.40 | $51.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $29.00 | ★ $110.90 |
| AVG Volume (30 Days) | 486.4K | ★ 1.8M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.19 | N/A |
| Revenue | ★ $2,745,461,000.00 | $98,675,000.00 |
| Revenue This Year | $25.41 | N/A |
| Revenue Next Year | $0.82 | $155.86 |
| P/E Ratio | $6.31 | ★ N/A |
| Revenue Growth | ★ 21.12 | N/A |
| 52 Week Low | $16.80 | $41.50 |
| 52 Week High | $27.88 | $90.32 |
Technical Indicators
Market Signals| Indicator | HG | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 48.33 |
| Support Level | $25.93 | $47.80 |
| Resistance Level | $27.88 | $53.10 |
| Average True Range (ATR) | 0.67 | 2.47 |
| MACD | -0.11 | 1.09 |
| Stochastic Oscillator | 37.55 | 79.48 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.